AAM
DNA icon

Azzad Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Azzad Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-673
Closed -$35.8K – 322
2023
Q1 		$35.8K Buy
673
+105
+18% +$6.65K 0.01% 315
2022
Q4 		$38.4K Buy
568
+170
+43% +$15.6K 0.01% 309
2022
Q3 		$49.6K Sell
398
-16
-4% -$1.91K 0.01% 397
2022
Q2 		$39.5K Buy
+414
New +$50.5K ﹤0.01% 391

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Azzad Asset Management's DNA Position: Q2 2023 in Review

Azzad Asset Management sold out of Ginkgo Bioworks (DNA) in Q2 2023, closing a stake of 673 shares — an estimated $35.8K sold.

Azzad Asset Management first reported a position in DNA in Q2 2022 and held it in 4 quarters. The position peaked at $49.6K in Q3 2022. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

  • Azzad Asset Management reported no remaining Ginkgo Bioworks position as of Q2 2023 after selling out during the quarter.
  • Azzad Asset Management sold 673 Ginkgo Bioworks shares in Q2 2023, an estimated $35.8K.
  • Azzad Asset Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 4 quarters.
  • Azzad Asset Management's Ginkgo Bioworks position peaked at $49.6K in Q3 2022.
  • 315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Azzad Asset Management's 13F filing for Q2 2023, filed 1 Apr 2024.